The earnings themselves are immaterial for a pre-revenue biotech. The stock will move on Sentynl's decision to exercise the alvelestat option (expected within a short period) and on any regulatory update for setrusumab by year-end 2026. Monitor for option exercise announcement and FDA/MHRA feedback on setrusumab path forward.
Price Chart
Executive Summary
Mereo BioPharma reported Q2 2026 results with zero revenue and a net loss of $7.0M, in line with consensus EPS of -$0.01. The key event is the recently announced option and license agreement with Sentynl Therapeutics for alvelestat, which provides a path to fund a Phase 3 study but remains an option, not a guaranteed upfront payment. Cash of $30.1M funds operations into late 2027, but the company remains a pre-revenue clinical-stage biotech with a $42M market cap, making the earnings themselves immaterial relative to the partnership news.
Key Financial Metrics
Key Facts
- Q2 2026 revenue was $0 (vs $500K in Q2 2025), net loss of $7.0M ($0.01 per share), in line with consensus EPS of -$0.01.
- Cash and cash equivalents of $30.1M at June 30, 2026, expected to fund operations into late 2027.
- Entered into option and license agreement with Sentynl Therapeutics for alvelestat; Sentynl has option to acquire U.S. commercial and global manufacturing rights for AATD-LD.
- Upon option exercise, Mereo eligible for $40M in upfront/R&D payments, up to $435M in milestones, and double-digit tiered royalties.
- Setrusumab Phase 3 studies (Orbit and Cosmic) missed primary endpoints but achieved statistical significance on key secondary endpoint (bone mineral density); regulatory discussions ongoing with FDA and MHRA.
- R&D expenses decreased to $1.8M from $5.4M in Q2 2025, primarily due to reduced spending on setrusumab and alvelestat.
Financial Impact
No revenue; net loss $7.0M; cash burn ~$10.9M in H1 2026; potential $40M upfront on alvelestat option exercise is contingent.
Risk Factors
- Sentynl may not exercise the alvelestat option, leaving Mereo without the $40M upfront and Phase 3 funding.
- Setrusumab failed Phase 3 primary endpoints; regulatory path forward is uncertain and may require additional costly trials.
- Cash runway into late 2027 is contingent on current burn rate; any delays or additional costs could shorten runway.
- Pre-revenue clinical-stage biotech with high dilution risk; market cap of $42M provides limited buffer against setbacks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342688 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | 8-K | $0.3115 $0.2780 | ▲ +10.75% | ▲ +10.37% | $0.2920 (+6.26%) |
Aug 11, 2026 11w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2920 (−4.58%) |
Aug 11, 2026 11w ago | Press Release | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2920 (−4.58%) |
Aug 11, 2026 11w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2920 (−4.58%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.3118 $0.3100 | ▼ −0.58% | ▼ −1.01% | $0.2920 (−6.35%) |
May 12, 2026 24w ago | Press Release | $0.2460 $0.2370 | ▲ +3.66% | ▲ +3.74% | $0.2920 (−18.70%) |
Mar 19, 2026 31w ago | Press Release | $0.3610 $0.3390 | ▼ −6.09% | ▼ −3.88% | $0.2920 (−19.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers